Letrozole Tablets Exporter India | Aromatase Inhibitor Breast Cancer Supplier

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Letrozole tablets are hormonal therapy medicines classified as aromatase inhibitors, primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. The formulation works by reducing estrogen production in the body, thereby slowing or stopping the growth of hormone-sensitive tumors.

In pharmaceutical export markets, Letrozole tablets exporter India and hormonal breast cancer medicine supplier India are widely searched by oncology distributors and importers. Genliva Wellness LLP, Himatnagar, operates as a pharma exporter India hormonal oncology medicines provider, supplying high-demand cancer therapies to international pharmaceutical companies, hospitals, and institutional buyers.

Letrozole tablets are a non-steroidal aromatase inhibitor designed to reduce estrogen production, helping control hormone-dependent tumor growth. The formulation supports effective and consistent therapy in hormone-sensitive conditions.

Aromatase inhibitor that suppresses estrogen synthesis
Targets hormone-dependent cancer growth pathways
Oral formulation for convenient administration
Provides consistent and controlled therapeutic effect
Suitable for long-term treatment under medical supervision
Manufactured under stringent cGMP and quality standards

This medication is widely used in the treatment of hormone receptor-positive breast cancer and other estrogen-dependent conditions. It is prescribed as part of specialized oncology and hormonal therapy regimens.

Hormone receptor-positive breast cancer (early and advanced stages)
Adjuvant therapy following surgery or other treatments
Metastatic breast cancer in postmenopausal women
Ovulation induction in infertility management (as per clinical use)
Helps reduce recurrence risk and disease progression

The formulation provides targeted hormonal control with reliable efficacy and patient convenience. It supports long-term disease management and improved outcomes.

Reduces estrogen levels effectively to control tumor growth
Oral therapy improves patient compliance
Suitable for extended treatment duration
Predictable and consistent therapeutic response
Stable formulation with good shelf life
Ideal for oncology and global pharmaceutical supply markets